Kinnate Biopharma Inc. Stock

Kinnate Biopharma Inc. is a clinical-stage precision oncology company. The Company is focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Company’s product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor which was designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors. Its early-stage programs include a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. The Company concentrates its efforts on addressing known oncogenic drivers for targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance.